blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3808349

EP3808349 - COMPOUNDS AND METHODS FOR TREATING CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.08.2023
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  02.09.2022
FormerGrant of patent is intended
Status updated on  31.03.2022
FormerRequest for examination was made
Status updated on  19.03.2021
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Mayo Foundation for Medical Education and Research
200 First Street S.W.
Rochester, MN 55905 / US
[2021/16]
Inventor(s)01 / COPLAND III, John A.
181 Greencrest Drive
Ponte Vedra Beach, FL 32082 / US
02 / TUN, Han W.
7717 Watermark Lane S.
Jacksonville, FL 32256-4109 / US
03 / CAULFIELD, Thomas R.
7519 Scarlet Ibis Lane
Jacksonville, FL 32256-2879 / US
04 / VON ROEMELING, Christina
2371 White Sands Drive
Jacksonville, FL 32216-4597 / US
05 / MARLOW, Laura Ann
13813 Jeremiah Rd
Jacksonville, FL 32224-7215 / US
 [2021/18]
Former [2021/16]01 / COPLAND III, John A.
181 Greencrest Drive
Ponte Vedra Beach, FL 32082 / US
02 / TUN, Han W.
7717 Watermark Lane S.
Jacksonville, FL 32256-4109 / US
03 / CAULFIELD, Thomas R.
7519 Scarlet Ibis Lane
Jacksonville, FL 32256-2879 / US
04 / VON ROEMELING, Christina
2371 White Sands Drive
Jacksonville, FL 32216-4597 / US
05 / MARLOW, Laura Ann
1105 Romaine Circle West
Jacksonville, FL 32225 / US
Representative(s)Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
[2021/16]
Application number, filing date20209314.207.08.2015
[2021/16]
Priority number, dateUS201462034429P07.08.2014         Original published format: US 201462034429 P
[2021/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3808349
Date:21.04.2021
Language:EN
[2021/16]
Type: B1 Patent specification 
No.:EP3808349
Date:05.10.2022
Language:EN
[2022/40]
Search report(s)(Supplementary) European search report - dispatched on:EP24.03.2021
ClassificationIPC:A61K31/496, A61K31/454, C07D213/75, C07D211/64, C07D295/192, C07D213/64, A61P35/00
[2021/16]
CPC:
C07D295/192 (EP,US); A61K31/44 (EP,US); A61K31/495 (EP,US);
A61K31/496 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP);
C07D211/64 (EP,US); C07D211/66 (EP,US); C07D213/64 (EP,US);
C07D213/75 (EP,US) (-)
C-Set:
A61K31/496, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/16]
TitleGerman:VERBINDUNGEN UND VERFAHREN ZUR BEHANDLUNG VON KREBS[2021/16]
English:COMPOUNDS AND METHODS FOR TREATING CANCER[2021/16]
French:COMPOSÉS ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER[2021/16]
Examination procedure23.11.2020Examination requested  [2021/16]
19.10.2021Amendment by applicant (claims and/or description)
01.04.2022Communication of intention to grant the patent
15.07.2022Fee for grant paid
15.07.2022Fee for publishing/printing paid
15.07.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15830331.3  / EP3177292
Divisional application(s)EP22199542.6  / EP4180041
Opposition(s)06.07.2023No opposition filed within time limit [2023/37]
Fees paidRenewal fee
23.11.2020Renewal fee patent year 03
23.11.2020Renewal fee patent year 04
23.11.2020Renewal fee patent year 05
23.11.2020Renewal fee patent year 06
27.08.2021Renewal fee patent year 07
29.08.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
IT05.10.2022
LT05.10.2022
LV05.10.2022
MC05.10.2022
NL05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
[2024/26]
Former [2024/16]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
MC05.10.2022
NL05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/51]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/38]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/37]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/35]AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/34]AT05.10.2022
DK05.10.2022
EE05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/33]AT05.10.2022
DK05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/25]AT05.10.2022
ES05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
PL05.10.2022
RS05.10.2022
SE05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/23]AT05.10.2022
ES05.10.2022
FI05.10.2022
LT05.10.2022
LV05.10.2022
NL05.10.2022
SE05.10.2022
NO05.01.2023
GR06.01.2023
PT06.02.2023
Former [2023/22]AT05.10.2022
ES05.10.2022
FI05.10.2022
LT05.10.2022
NL05.10.2022
SE05.10.2022
NO05.01.2023
PT06.02.2023
Former [2023/20]LT05.10.2022
NL05.10.2022
NO05.01.2023
Former [2023/17]NL05.10.2022
Documents cited:Search[A]WO2008120759  (JAPAN TOBACCO INC [JP], et al) [A] 1-14 * the whole document ** page 5; example 1 *;
 [A]  - "1-Piperazinecarboxamide, 4-benzoyl-N-[2-[[(1,1-dimethylethyl)amino]carbonyl]phenyl]-", REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20120812), Database accession no. 1390035-79-6, XP002777974 [A] 1 * abstract *
 [A]  - C. A. VON ROEMELING ET AL, "Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma", CLINICAL CANCER RESEARCH, US, (20130430), vol. 19, no. 9, doi:10.1158/1078-0432.CCR-12-3249, ISSN 1078-0432, pages 2368 - 2380, XP055448847 [A] 9 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-3249
 [A]  - J. Y. LEUNG ET AL, "Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target: Death by Stress", CLINICAL CANCER RESEARCH, US, (20130524), vol. 19, no. 12, doi:10.1158/1078-0432.CCR-13-0800, ISSN 1078-0432, pages 3111 - 3113, XP055448856 [A] 9 * the whole document * * page 3112, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0800
 [A]  - YUJIAN ZHANG ET AL, "Positive feedback loop and synergistic effects between hypoxia-inducible factor-2[alpha] and stearoyl-CoA desaturase-1 promote tumorigenesis in clear cell renal cell carcinoma", CANCER SCIENCE, JP, (20130303), vol. 104, no. 4, doi:10.1111/cas.12108, ISSN 1347-9032, pages 416 - 422, XP055448838 [A] 9 * abstract *

DOI:   http://dx.doi.org/10.1111/cas.12108
 [A]  - V. FRITZ ET AL, "Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice", MOLECULAR CANCER THERAPEUTICS, US, (20100601), vol. 9, no. 6, doi:10.1158/1535-7163.MCT-09-1064, ISSN 1535-7163, pages 1740 - 1754, XP055448871 [A] 9 * abstract *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-09-1064
 [A]  - D. LUYIMBAZI ET AL, "Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer", MOLECULAR CANCER THERAPEUTICS, US, (20100928), vol. 9, no. 10, doi:10.1158/1535-7163.MCT-09-0980, ISSN 1535-7163, pages 2770 - 2784, XP055448876 [A] 9 * abstract *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-09-0980
 [A]  - LEI LI ET AL, "SCD1 Expression Is Dispensable for Hepatocarcinogenesis Induced by AKT and Ras Oncogenes in Mice", PLOS ONE, (20130919), vol. 8, no. 9, doi:10.1371/journal.pone.0075104, pages 1 - 12, XP055448885 [A] 9 * abstract *

DOI:   http://dx.doi.org/10.1371/journal.pone.0075104
 [A]  - X. DU ET AL, "FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth", CANCER RESEARCH, US, (20120926), vol. 72, no. 22, doi:10.1158/0008-5472.CAN-12-1329, ISSN 0008-5472, pages 5843 - 5855, XP055448883 [A] 9 * abstract *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-1329
by applicantUS6066730
 US6297217
 US6548668
 US6699835
 US7109323
 WO2009020448
 WO2009051581
 US7531526
 WO2009154737
 US7687456
 WO2010036357
 US7691852
 WO2011123502
 US8080576
 US8080545
 US8088741
 US8357683
 US8431571
    - GUILLOU HZADRAVEC DMARTIN PGJACOBSSON A, "The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice", Prog Lipid Res, (20100400), vol. 49, no. 2, doi:10.1016/j.plipres.2009.12.002, pages 186 - 199, XP026911078

DOI:   http://dx.doi.org/10.1016/j.plipres.2009.12.002
    - BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - VON ROEMELING, C.A. et al., J. Clin. Endocrinol. Metab., (20150500), vol. 100, no. 5, pages E697 - E709
    - "GenBank", Database accession no. AF097514.1
    - BRISTOL-MYERS SQUIBB RD, ROONGTA et al., Mol. Cancer Res., (20110000), vol. 9, no. 11, pages 1551 - 1561
    - OBALLA et al., J. Med. Chem., (20110000), vol. 54, no. 14, pages 5082 - 5096
    - MERCK, LI et al., Bioorganic & Medicinal Chemistry Letters, (20090000), vol. 19, no. 7, pages 5214 - 5217
    - UTO et al., Eur. J. Med. Chem., (20100000), vol. 45, pages 4788 - 4796
    - LEGER SBLACK WCDESCHENES DDOLMAN SFALGUEYRET JPGAGNON MGUIRAL SHUANG ZGUAY JLEBLANC Y, "Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438", Bioorg Med Chem Lett, (20100000), vol. 20, no. 22, pages 6366 - 502
    - XIN et al., Bioorganic & Medicinal Chemistry Letters, (20080000), vol. 18, no. 15, pages 4298 - 4302
    - IGAL, Carcinogenesis, (20100000), vol. 31, no. 9, pages 1509 - 1515
    - UTO et al., Eur. J. Med. Chem., (20110000), vol. 46, pages 1892 - 1896
    - LIU, G., Expert Opin Ter Pat, (20090000), vol. 19, no. 9, pages 1169 - 91
    - MASON P et al., PLoS ONE, (20120000), vol. 7, no. 3, page 33823
    - SASTRY, G.M. et al., J. Chem. Inf. Model., (20130000), vol. 53, no. 4, pages 1531 - 1542
    - KALID, O. et al., J. Comput. Aided Mol. Des., (20120000), vol. 26, pages 1217 - 1228
    - FU, J. et al., Bioorg. Med. Chem. Lett., (20120000), vol. 22, no. 2, pages 6848 - 6853
    - SASTRY, G.M. et al., J. Chem. Inf. Model., (20110000), vol. 51, pages 2455 - 2466
    - MOHAMADI, F. et al., J Comput Chem, (19900000), vol. 11, no. 4, pages 440 - 467
    - JORGENSEN, WL et al., J Am Chem Soc, (19880316), vol. 110, no. 6, pages 1657 - 1666
    - CAULFIELD, T. et al., Proteins, (20121100), vol. 80, no. 11, pages 2489 - 2500
    - LOVING, K. et al., Journal of computer-aided molecular design, (20090800), vol. 23, no. 8, pages 541 - 554
    - VIVOLI, M. et al., Mol Pharmacol, (20120300), vol. 81, no. 3, pages 440 - 454
    - FRIESNER, RA et al., Journal of medicinal chemistry, (20061019), vol. 49, no. 21, pages 6177 - 6196
    - KRIEGER EDUNBRACK RL, JR.HOOFT RWKRIEGER B, "Assignment of protonation states in proteins and ligands: combining pKa prediction with hydrogen bonding network optimization", Methods Mol Biol, (20120000), vol. 819, pages 405 - 421
    - KRIEGER EJOO KLEE J et al., "Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8", Proteins, (20090000), vol. 9, pages 114 - 122
    - ZHOU HSKOLNICK J., "Protein structure prediction by pro-Sp3-TASSER", Biophys J., (20090318), vol. 96, no. 6, pages 2119 - 2127
    - ZHOU HSKOLNICK J., "Improving threading algorithms for remote homology modeling by combining fragment and template comparisons", Proteins, (20100700), vol. 78, no. 9, pages 2041 - 2048
    - HALGREN T, "New method for fast and accurate binding-site identification and analysis", Chem. Biol. Drug Des., (20070000), vol. 69, pages 146 - 148
    - HALGREN T, "Identifying and characterizing binding sites and assessing druggability", J. Chem. Inf. Model., (20090000), vol. 49, doi:10.1021/ci800324m, pages 377 - 389, XP055753223

DOI:   http://dx.doi.org/10.1021/ci800324m
    - WATTS KSDALAL PMURPHY RBSHERMAN WFRIESNER RASHELLEY JC, "ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers", J.Chem. Inf. Model., (20100000), vol. 50, pages 534 - 546
    - SUN HTAWA GWALLQVIST A, "Classification of scaffold-hopping approaches", Drug discovery today., (20120400), vol. 17, no. 7-8, pages 310 - 324
    - SPERANDIO OANDRIEU OMITEVA MA et al., "MED-SuMoLig: A New Ligand-Based Screening Tool for Efficient Scaffold Hopping", Journal of Chemical Information and Modeling, (20070000), vol. 47, no. 3, pages 1097 - 1110
    - BOHM HJFLOHR ASTAHL M, "Scaffold Hopping", Drug Discov Today: Technologies, (20040000), vol. 1, no. 3, doi:10.1016/j.ddtec.2004.10.009, pages 217 - 224, XP004767956

DOI:   http://dx.doi.org/10.1016/j.ddtec.2004.10.009
    - HERR AJWILLS NMNELSON CCGESTELAND RFATKINS JF, "Drop-off during ribosome hopping", J Mol Biol, (20010000), vol. 311, no. 3, doi:10.1006/jmbi.2001.4899, pages 445 - 452, XP004472400

DOI:   http://dx.doi.org/10.1006/jmbi.2001.4899
    - SANDOR MKISS RKESERU GM, "Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes", Journal of Chemical Information and Modeling, (20100600), vol. 50, no. 6, pages 1165 - 1172
    - TUN HWMARLOW LAVON ROEMELING CACOOPER SJKREINEST PWU KLUXON BASINHA MANASTASIADIS PZCOPLAND JA, "Pathway signature and cellular differentiation in clear cell renal cell carcinoma", PLoS One, (20100000), vol. 5, no. 5, doi:10.1371/journal.pone.0010696, page e10696, XP055279450

DOI:   http://dx.doi.org/10.1371/journal.pone.0010696
    - COPLAND JAMARLOW LAKURAKATA S et al., "Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1", Oncogene, (20060413), vol. 25, no. 16, doi:10.1038/sj.onc.1209267, pages 2304 - 2317, XP002468075

DOI:   http://dx.doi.org/10.1038/sj.onc.1209267
    - SCHMITTGEN TDLIVAK KJ, "Analyzing real-time PCR data by the comparative C(T) method", Nat Protoc, (20080000), vol. 3, no. 6, doi:10.1038/nprot.2008.73, pages 1101 - 8, XP055137608

DOI:   http://dx.doi.org/10.1038/nprot.2008.73
    - VON ROEMELING CAMARLOW LAWEI JJ et al., "Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma", Clin Cancer Res, (20130501), vol. 19, no. 9, doi:10.1158/1078-0432.CCR-12-3249, pages 2368 - 2380, XP055448847

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-3249
    - LIU GLYNCH JKFREEMAN J et al., "Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors", Journal of medicinal chemistry, (20070628), vol. 50, no. 13, doi:10.1021/JM070219P, pages 3086 - 3100, XP002545150

DOI:   http://dx.doi.org/10.1021/JM070219P
    - VOSS MDZOLLER GMATTER H et al., "Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1", European journal ofpharmacology, (20130505), vol. 707, no. 1-3, pages 140 - 146
    - ROONGTA UVPABALAN JGWANG X et al., "Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy", Mol Cancer Res, (20111100), vol. 9, no. 11, doi:10.1158/1541-7786.MCR-11-0126, pages 1551 - 1561, XP055072211

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-11-0126
    - WANG YSHEN JARENZANA NTIRASOPHON WKAUFMAN RJPRYWES R, "Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response", J Biol Chem, (20000901), vol. 275, no. 35, pages 27013 - 27020
    - XIN ZZHAO HSERBY MDLIU BLIU MSZCZEPANKIEWICZ BGNELSON LTSMITH HTSUHAR TSJANIS RS, "Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors", Bioorg Med Chem Lett, (20080000), vol. 18, no. 15, doi:10.1016/j.bmcl.2008.06.088, pages 4298 - 302, XP023521536

DOI:   http://dx.doi.org/10.1016/j.bmcl.2008.06.088
    - ROONGTA UVPABALAN JGWANG XRYSECK RPFARGNOLI JHENLEY BJYANG WPZHU JMADIREDDI MTLAWRENCE RM, "Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy", Mol Cancer Res, (20110000), vol. 9, no. 11, doi:10.1158/1541-7786.MCR-11-0126, pages 1551 - 61, XP055072211

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-11-0126
    - VON ROEMELING CAMARLOW LAWEI JJCOOPER SJCAULFIELD TRWU KTAN WWTUN HWCOPLAND JA, "Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma", Clin Cancer Res, (20130000), vol. 19, no. 9, doi:10.1158/1078-0432.CCR-12-3249, pages 2368 - 80, XP055448847

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-3249
    - XU CBAILLY-MAITRE BREED JC, "Endoplasmic reticulum stress: cell life and death decisions", J Clin Invest, (20050000), vol. 115, no. 10, pages 2656 - 64
    - WALTER PRON D, "The unfolded protein response: from stress pathway to homeostatic regulation", Science, (20110000), vol. 334, no. 6059, pages 1081 - 6
    - HETZ CCHEVET EHARDING HP, "Targeting the unfolded protein response in disease", Nat Rev Drug Discov, (20130000), vol. 12, no. 9, doi:10.1038/nrd3976, pages 703 - 19, XP055557628

DOI:   http://dx.doi.org/10.1038/nrd3976
    - KIM IXU WREED JC, "Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities", Nat Rev Drug Discov, (20080000), vol. 7, no. 12, pages 1013 - 30
    - CHOU TCTALALAY P, "Analysis of Combined Drug Effects - a New Look at a Very Old Problem", Trends in Pharmacological Sciences, (19830000), vol. 4, no. 11, doi:10.1016/0165-6147(83)90490-X, pages 450 - 4, XP025996997

DOI:   http://dx.doi.org/10.1016/0165-6147(83)90490-X
    - MARLOW LAD'INNOCENZI JZHANG YROHL SDCOOPER SJSEBO TGRANT CMCIVER BKASPERBAUER JLWADSWORTH JT, "Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target", J Clin Endocrinol Metab, (20100000), vol. 95, no. 12, pages 5338 - 47
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.